Accueil>>Signaling Pathways>> JAK/STAT Signaling>> STAT>>AC-4-130

AC-4-130

Catalog No.GC62272

AC-4-130 est un puissant inhibiteur du domaine STAT5 SH2. AC-4-130 se lie directement À STAT5 et perturbe l'activation, la dimérisation, la translocation nucléaire et la transcription génique dépendante de STAT5. L'AC-4-130 induit l'arrêt du cycle cellulaire et l'apoptose dans les cellules leucémiques induites par FLT3-ITD. L'AC-4-130 a une activité anticancéreuse et peut bloquer efficacement les niveaux pathologiques d'activité de STAT5 dans la leucémie myéloÏde aiguë (LMA).

Products are for research use only. Not for human use. We do not sell to patients.

AC-4-130 Chemical Structure

Cas No.: 1834571-82-2

Taille Prix Stock Qté
5 mg
225,00 $US
En stock
10 mg
342,00 $US
En stock
25 mg
675,00 $US
En stock
50 mg
1 170,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AC-4-130 is a potent STAT5 SH2 domain inhibitor. AC-4-130 directly binds to STAT5 and disrupts STAT5 activation, dimerization, nuclear translocation, and STAT5-dependent gene transcription. AC-4-130 induces cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 has anti-cancer activity and can efficiently block pathological levels of STAT5 activity in acute myeloid leukemia (AML)[1].

AC-4-130 (0.1-100 µM; 72 hours) leads to a significant increase in apoptosis in a dose-dependent and time-dependent manner in MV4-11 or MOLM-13 cells[1]. AC-4-130 (2, 5 µM; 72 hours) induces cell cycle arrest with an increase in G0/G1 arrested cells and a concomitant reduction in cells in S or G2/M[1]. AC-4-130 (0.5-2; 24 hours) reveals reduced pY-STAT5 levels both in the cytoplasm and nucleus[1]. AC-4-130-mediated STAT5 inhibition efficiently blocks the proliferation and clonogenic growth of primary human AML cells, while healthy CD34+ cells are less sensitive[1].

[1]. Bettina Wingelhofer, et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia. 2018 May;32(5):1135-1146.

Avis

Review for AC-4-130

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AC-4-130

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.